Clinical and experimental evidences support a link between the complement system and the pathogenesis of diabetes complications. CD59, an extracellular cell membrane-anchored protein, inhibits formation of the membrane attack complex (MAC), the main effector of complementmediated tissue damage. This complement regulatory activity of human CD59 (hCD59) is inhibited by hyperglycemia-induced E-amino glycation of Lys 41 . Biochemical and structural analyses of glycated proteins with known three-dimensional structure revealed that glycation of E-amino lysyl residues occurs predominantly at "glycation motives" that include lysyl/lysyl pairs or proximity of a histidyl residue, in which the imidazolyl moiety is 5Å from the E-amino group. hCD59 contains a Protein glycation is a major mechanism of tissue damage in diabetes. 29 The reaction of glucose with a-or E-amino groups in proteins starts with the formation of a Schiff base or aldimine, followed by tautomerization to the more stable ketoamine via the Amadori rearrangement. [30] [31] [32] It has long been observed that despite the presence of many amino groups on the surface of proteins few E-amino groups are glycated to a significant extent in vivo. 33,34 Initial attempts to elucidate this intriguing observation suggested that properties of nearby amino acids could play a role in determining whether a given lysine is glycated. 33, 34 Later, identification of E-amino glycation in some Lys/Lys pairs 31 led to sequence logo statistical analysis of glycated lysine residues as well as proteomic analyses of glycated proteins in plasma and erythrocytes. These efforts generated sequence-based glycation predictors derived from the primary structure of glycated proteins. 35, 36 However, sequence-based predictors of E-amino lysine glycation fail to predict the three-dimensional structure of proteins and the potential involvement of a catalytic amino acid residue that is in proximity to the glycated lysine in the three-dimensional protein structure (3D) but distant in the primary sequence. 35, 36 The identification of glycated amino groups in proteins with known 3D revealed that E-amino glycation preferably occurs at "glycation motives" such as Lys/ His in which an imidazolyl moiety located at 5Å from the E-amino group of a Lys provides acid-base catalysis for the aldimine/ketoamine tautomerization. 31, 32, 37, 38 For example, the b chain of hemoglobin dis- 
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| I N TR ODU C TI ON
The complement system is an effector of both adaptive and innate immunity. The system can be activated through three different cascades known as the classical, the alternative and the mannose-binding lectin (MBL) pathways. 1, 2 The three pathways share a common late reaction sequence that leads to the generation of the membrane attack complex (MAC), a trans-membrane pore that is the main effector of complement-mediated tissue damage. Insertion of the MAC into red blood cell membranes causes colloidosmotic lysis while insertion into nucleated cells can activate intracellular signaling cascades and trigger the release of cytokines and growth factors that stimulate proliferation, inflammation and thrombosis [3] [4] [5] [6] [7] [8] [9] as characteristically seen in the target organs of complement activation.
To protect "self" cells from the devastating consequences of unre- [11] [12] [13] In animal models, we have reported that ablation of CD59 promoted accelerated atherosclerosis with occlusive coronary disease and premature death, which were attenuated by transgenic overexpression of human CD59 in the endothelium.
14 Regarding diabetes, a body of clinical and experimental evidence supports a pathogenic link between the complement system, CD59, and the pathogenesis and progression of diabetes complications [15] [16] [17] [18] [19] [20] [21] [22] [23] and reviewed in Ref. 24 . In animal models, we recently reported that diabetic mCD59 deficient mice develop accelerated atherosclerosis as compared with diabetic mCD59 wild type mice. 25 There are different ways in which the "delicate balance" between complement activation and restriction can be potentially broken in diabetes. Autoantibodies to glycated and glycol-oxidized proteins can activate the classical pathway, 26, 27 fructosamines and advanced glycation end products (AGEs) reportedly activate the lectin pathway. 18, 28 Of all the putative mechanisms that potentially contribute to complement-mediated tissue damage in diabetes, inactivation by nonenzymatic glycation of hCD59 is the most extensively studied and documented.
Protein glycation is a major mechanism of tissue damage in diabetes. 29 The reaction of glucose with a-or E-amino groups in proteins starts with the formation of a Schiff base or aldimine, followed by tautomerization to the more stable ketoamine via the Amadori rearrangement. [30] [31] [32] It has long been observed that despite the presence of many amino groups on the surface of proteins few E-amino groups are glycated to a significant extent in vivo. 33, 34 Initial attempts to elucidate this intriguing observation suggested that properties of nearby amino acids could play a role in determining whether a given lysine is glycated. 33, 34 Later, identification of E-amino glycation in some Lys/Lys pairs 31 led to sequence logo statistical analysis of glycated lysine residues as well as proteomic analyses of glycated proteins in plasma and erythrocytes. These efforts generated sequence-based glycation predictors derived from the primary structure of glycated proteins. 35, 36 However, sequence-based predictors of E-amino lysine glycation fail to predict the three-dimensional structure of proteins and the potential involvement of a catalytic amino acid residue that is in proximity to the glycated lysine in the three-dimensional protein structure (3D) but distant in the primary sequence. 35, 36 The identification of glycated amino groups in proteins with known 3D revealed that E-amino glycation preferably occurs at "glycation motives" such as Lys/ His in which an imidazolyl moiety located at 5Å from the E-amino group of a Lys provides acid-base catalysis for the aldimine/ketoamine tautomerization. 31, 32, 37, 38 For example, the b chain of hemoglobin dis- Analyzing the NMR structure of human CD59, 40 we recognized the presence of a putative glycation-motif formed by amino acid residues Lys 41 and His
44
. To test experimentally the presence of a glycation motif in human CD59, we expressed recombinant human CD59
(hCD59WT) and a mutant lacking the H44 residue (hCD59H44Q), and
showed that hCD59WT but not the hCD59H44Q mutant was inhibited by glycation. It is known, however, that in vitro protein glycation studies require concentrations of glucose that are extremely high (0.5-1M) 41 as compared with either the physiological glucose concentration The results reported here provide the first in vivo demonstration of the glycation-motif concept; they suggest that the glycation motif in hCD59 may confer humans a higher risk of developing vascular disease in response to hyperglycemia.
| M E TH ODS

| Animals
Animal studies were approved by the Harvard Medical School's Institutional Animal Care and Use Committee (IACUC). Mice were housed in micro-isolator cages in a pathogen-free animal facility, fed a regular chow diet and kept on 12 hours light/12 hours dark cycle.
| Generation of transgenic mice expressing human CD59
Transgenic mice expressing either wild type (Tg-hCD59WT) or H44Q mutant (Tg-hCD59H44Q) human CD59 in erythrocytes were generated using the construct described previously. 42 The transgenic vector consisted of the human locus control region (LCR), alpha globin gene promoter, and hCD59 cDNA (either WT or H44Q mutant, from 5 0 to 3 0 ). These mice were originally generated in a mixed genetic background and were backcrossed for more than 10 generations to C57BL/6J background. Age-matched nontransgenic C57BL/6J mice (Non-Tg) were used as controls. The successful generation of these mice was determined by both Northern blot and FACS analysis of erythrocytes, as we previously described in details. 43 
| Induction of diabetes
| FACS analysis
Blood was collected from tail tip in heparinized capillary and mouse red blood cells (mRBCs) were isolated. Cells were washed twice with phosphate-buffered saline (PBS) and resuspended in PBS containing 
| Hemolytic assay
The protective activity of hCD59 against human MAC mediated lysis of mRBCs was determined by a hemolysis protection assay using mRBCs exposed to the human membrane attack complex (MAC), as described in Ref. 16 . Briefly, a suspension of mRBCs in gelatin veronal buffer with calcium and magnesium (GVB
11
) was challenged with purified human C5b-6, C7, C8, and C9 (Complement Technologies, Texas, USA) that were added sequentially to form human MAC. MAC-mediated lysis of mRBCs was quantitated by measuring the absorbance of released hemoglobin at 405 nm. Results were expressed as percent of mRBC lysis.
| Western blot analysis
Mouse ghost RBC lysate was prepared as described 44 (data not shown).
| Statistical analysis
Experimental results are shown as the Mean 6 S.D. The difference between two groups was evaluated with 2-tailed Student's t-test for 
| R E SU LTS
| STZ-induced hyperglycemia in mice
To assess in vivo the preferential glycation of a Lys 41 residue in proximity to His 44 within a glycation motif in hCD59, we generated transgenic mice expressing in red blood cells (mRBC) human CD59, either the glycation-sensitive wild type (Tg-hCD59WT) or the glycation resistant H44Q mutant (Tg-hCD59H44Q) designed to break the putative glycation motif while preserving the Lys 41 (Supporting Information Figure S1 ). The transgenic mice were made diabetic by multiple low-dose injection of streptozotocin. Expression of either wild type or H44Q mutant hCD59 did not affect the rate or extent of hyperglycemia in transgenic mice when compare to the nontransgenic animals ( Figure 1A ). Eight weeks after STZ injection (blood glucose 400 mg/dL), the mRBC were tested to assess both (1) in vivo glycation of hCD59 by
Western blot analysis with a monoclonal antibody highly specific for Lys 41 glycated hCD59 (Supporting Information Figure S2 and Materials and Methods), and (2) FIG URE 3 The activity of transgenic hCD59WT but not of the transgenic hCD59H44Q44 mutant is inhibited in diabetic mice. Mice were made diabetic by injection of STZ. After two weeks, the activity of transgenic hCD59 was assessed ex vivo using the hemolytic assay shown in Figure 2A . The figure is a box/whisker style plot representing lysis of mRBC by human MAC form nondiabetic (ND) and diabetic mice (D . 45, 46 To assess the functional consequence of hCD59 glycation in vivo, we established a hemolytic assay to measure hCD59 activity with a slight modification of the one described in reference. 16 Briefly, the assay measures the activity of transgenically expressed hCD59 through the hemolysis of isolated mRBC following the sequential addition of purified human terminal complement components (C5b-6, C7, C8, and C9). Added in this sequence, the terminal complement components lyse mRBC by formation of the human MAC (Figure 2A ).
Due to the high species specificity of CD59 (mouse CD59 is active against mouse complement but does not protect mouse cells against human com- 3.4 | Glycation and inactivation of wild type hCD59 in vivo Figure 3 shows that the protection conferred by Tg-hCD59 to mRBC exposed to human MAC was lost in diabetic mice expressing TghCD59WT (red filled box) but preserved in mRBCs expressing the TghCD59H44Q mutant (blue filled box). The increased lysis of mRBC observed in diabetic transgenic mice expressing Tg-hCD59WT was due to loss of hCD59 protecting activity as (1) it was rescued by in vitro addition of purified hCD59 ( Figure 3 , red hatched box), (2) hyperglycemia did not affect the membrane density of transgenic hCD59, as
shown by FACS analysis in Figure 1B , and (3) neither the expression of the transgenic proteins nor hyperglycemia affected the osmotic fragility of the mRBC (Supporting Information Figure S3 ).
| D I SCUSSION
The results presented here provide the first in vivo experimental demonstration of the operation of a glycation motif in a human protein, a concept initially derived from biochemical and structural analysis of glycated proteins. From a human diabetes and complications perspective, the significance of the glycation motif in hCD59 is highlighted by (1) the emerging clinical and experimental evidence revealing that the complement system and glycation of CD59 play a role in the pathogenesis of the multiple complications of human diabetes, reviewed in Ref. 24) , and (2) the fact that the His 44 residue of hCD59 is absent in CD59 from any other animal species sequenced to date 45 (Supporting Information Table S1 ). 
